Organon & Co | OGN - Net Income

Stock Price
13.40
Daily Change
0.04 0.30%
Monthly
43.62%
Yearly
48.48%
Q2 Forecast
13.13

Organon & Co reported $-205M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Celltrion KRW 8.88B 322.47B Dec/2025
Cspc Pharmaceutical CNY 370.72M 592.81M Dec/2025
Deva Holding AS TRY 583.98M 319.1M Sep/2023
Dianthus Therapeutics USD -64.43M 27.67M Dec/2025
Divis Laboratories Ltd INR 5.83B 1.06B Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Kangmei Pharma CNY -3.82M 12.21M Sep/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Laboratorios Farma EUR 103.69M 37.04M Dec/2023
Malin Corporation EUR -1.1M 2.2M Dec/2023
Medical Developments International AUD -226K 121K Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Neuren Pharmaceuticals AUD 15.4M 7.88M Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Organigram Holdings CAD 19.97M 57.93M Dec/2025
Organon & Co USD -205M 365M Dec/2025
Ovoca Bio EUR -765K 4.89M Jun/2025
Pharma Mar EUR 1.53M 58.13M Mar/2026
Qiagen NV USD 107.83M 22.21M Dec/2025
Sartorius EUR 56.2M 37M Mar/2026
Sino Biopharmaceutical CNY 3.39B 2.91B Jun/2025
Tilray USD -44.93M 44.61M Sep/2025
Zealand Pharma A/S -379.12M 25.12M Dec/2025